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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Turkish language.
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase
explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects,
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and
discriminant validity). A total of 466 JIA patients (13.7% systemic, 40.6% oligoarticular, 22.5% RF negative poly-arthritis,
and 23.2% other categories) and 93 healthy children were enrolled in four centres. The JAMAR components discriminated
well-healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion,
the Turkish version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine
clinical practice and clinical research.
Keywords Juvenile idiopathic arthritis · Disease status · Functional ability · Health-related quality of life · JAMAR

Introduction
The aim of the present study was to cross-culturally adapt
and validate the Turkish parent, child/adult version of the
Juvenile Arthritis Multidimensional Assessment Report
The local members of the Paediatric Rheumatology International
Trials Organisation (PRINTO) participating in the project
are listed in the dedicated tables no. 2 and 3 of “https://doi.
org/10.1007/s00296-018-3944-1 / Cross-cultural adaptation
and psychometric evaluation of the Juvenile Arthritis
Multidimensional Assessment Report (JAMAR) in 54 languages
across 52 countries: review of the general methodology”.
* Erkan Demirkaya
erkandemirkaya@yahoo.com; dottore_erkan@yahoo.com
* Nicolino Ruperto
nicolaruperto@gaslini.org
https://www.printo.it

(JAMAR) [1] in patients with juvenile idiopathic arthritis
(JIA). The JAMAR assesses the most relevant parent/patient
reported outcomes in JIA, including overall well-being,
functional status, health-related quality of life (HRQoL),
pain, morning stiffness, disease activity/status/course,
articular and extra-articular involvement, drug-related side
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study conducted by the Paediatric Rheumatology International Trials
Organisation (PRINTO) [2] aimed to evaluate the Epidemiology, Outcome and Treatment of Childhood Arthritis
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adaptation and validation of the parent and patient versions of the
JAMAR in the Turkish language.

Extended author information available on the last page of the article

13

Vol.:(0123456789)

S396

Rheumatology International (2018) 38 (Suppl 1):S395–S402

Materials and methods
The methodology employed has been described in detail in
the introductory paper of the supplement [4]. In brief, it was
a cross-sectional study of JIA children, classified according
to the ILAR criteria [5, 6] and enrolled from July 2012 to
October 2014. Children were recruited after Ethics Committee approval and consent from at least one parent.

The JAMAR
The JAMAR [1] includes the following 15 sections:
1.

2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.

assessment of physical function (PF) using 15-items
in which the ability of the child to perform each task
is scored as follows: 0 = without difficulty, 1 = with
some difficulty, 2 = with much difficulty, 3 = unable to
do and not applicable if it was not possible to answer
the question or the patient was unable to perform the
task due to their young age or to reasons other than
JIA. The total PF score ranges from 0 to 45 and has
three components: PF-lower limbs (PF-LL); PF-hand
and wrist (PF-HW); and PF-upper segment (PF-US)
each scoring from 0 to 15 [7]. Higher scores indicating
higher degree of disability [8–10];
rating of the intensity of the patient’s pain on a
21-numbered circle visual analogue scale (VAS) [11];
assessment of the presence of joint pain or swelling
(present/absent for each joint);
assessment of morning stiffness (present/absent);
assessment of extra-articular symptoms (fever and
rash) (present/absent);
rating of the level of disease activity on a 21-circle
VAS;
rating of disease status at the time of the visit (categorical scale);
rating of disease course from previous visit (categorical scale);
checklist of the medications the patient is taking (list
of choices);
checklist of side effects of medications;
report of difficulties with medication administration
(list of items);
report of school/university/work problems caused by
the disease (list of items);
assessment of HRQoL, through the physical health
(PhH), and psychosocial health (PsH) sub-scales (five
items each) and a total score. The four-point Likert
response, referring to the prior month, are ‘never’
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
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able’ column was included in the parent version of the
questionnaire to designate questions that cannot be
answered because of developmental immaturity. The
total HRQoL score ranges from 0 to 30, with higher
scores indicating worse HRQoL. A separate score for
PhH and PsH (range 0–15) can be calculated [12–14];
14. rating of the patient’s overall well-being on a 21-numbered circle VAS;
15. a question about satisfaction with the outcome of the
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent
proxy-report (child’s age 2–18), one for child self-report,
with the suggested age range of 7–18 years, and one for
adults.

Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted
according to international guidelines with 2–3 forward and
backward translations. In those countries for which the translation of JAMAR had been already cross-cultural adapted in
a similar language (i.e., Spanish in South American countries), only the probe technique was performed. Reading
comprehension and understanding of the translated questionnaires were tested in a probe sample of ten JIA parents
and ten patients.
Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive
JIA patients or all consecutive patients seen in a 6-month
period and to administer the JAMAR to 100 healthy children
and their parents.
The statistical validation phase explored the descriptive
statistics and the psychometric issues [16]. In particular, we
evaluated the following validity components: the first Likert assumption (mean and standard deviation [SD] equivalence); the second Likert assumption or equal item-scale
correlations (Pearson r: all items within a scale should contribute equally to the total score); third Likert assumption
(item internal consistency or linearity for which each item
of a scale should be linearly related to the total score that is
90% of the items should have Pearson r ≥ 0.4); floor/ceiling
effects (frequency of items at lower and higher extremes of
the scales, respectively); internal consistency, measured by
the Cronbach’s alpha, interscale correlation (the correlation
between two scales should be lower than their reliability
coefficients, as measured by Cronbach’s alpha); test–retest
reliability or intra-class correlation coefficient (reproducibility of the JAMAR repeated after 1 or 2 weeks); and construct
validity in its two components: the convergent or external
validity which examines the correlation of the JAMAR subscales with the 6 JIA core-set variables, with the addition
of the parent assessment of disease activity and pain by the
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Spearman’s correlation coefficients (r) [17] and the discriminant validity, which assesses whether the JAMAR discriminates between the different JIA categories and healthy
children [18]. Quantitative data were reported as medians
with first and third quartiles and categorical data as absolute
frequencies and percentages.
The complete Turkish parent and patient versions of the
JAMAR are available upon request to PRINTO.

Results
Cross‑cultural adaptation
The Turkish JAMAR was fully cross-culturally adapted from
the standard English version with three forward and two
backward translations with concordance in 119/123 translation lines (96.7%) for the parent version and 107/120 lines
(89.2%) for the child version.
Of the 123 lines in the parent version of the JAMAR, 118
(96%) were understood by at least 80% of the 10 parents
tested (median = 100%; range: 20–100%); 114/120 (95%)
lines of the patient version of the JAMAR were understood
by at least 80% of the children (median = 100%; range:
70–100%). Lines 10, 55, 57, 113, and 114 of parent version
of the Turkish JAMAR and lines 9, 51, 53, 55, 107, and
110 of the child version were modified according to parents/
children suggestions after the probe technique.

Demographic and clinical characteristics
of the subjects
A total of 468 JIA patients and 95 healthy children (total of
563 subjects) were enrolled at five paediatric rheumatology
centres. Two patients and two healthy children did not give
the consent to use their data.
In the remaining 466 JIA subjects, the JIA categories
were 13.7% with systemic arthritis, 40.6% with oligoarthritis, 22.5% with RF negative poly-arthritis, 2.4% with RF
positive poly-arthritis, 3.2% with psoriatic arthritis, 15%
with enthesitis related arthritis, and 2.6% with undifferentiated arthritis (Table 1).
A total of 555/559 (99.3%) subjects had the parent version of the JAMAR completed by a parent (463 from parents
of JIA patients and 92 from parents of healthy children). The
JAMAR was completed by 364/555 (65.6%) mothers and
191/555 (34.4%) fathers. The child version of the JAMAR
was completed by 438/555 (78.9%) children age 6 or older.
In addition, patients younger than 7 years, capable to assess
their personal condition and able to read and write, were
asked to fill in the patient version of the questionnaire.

S397

Discriminant validity
The JAMAR results are presented in Table 1, including the
scores [median (1st–3rd quartile)] obtained for the PF, the
PhH, the PsH sub-scales, and total score of the HRQoL
scales. The JAMAR components discriminated well between
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had
a greater level of disability and pain, as well as a lower
HRQoL than their healthy peers.

Psychometric issues
The main psychometric properties of both parent and child
versions of the JAMAR are reported in Table 2. The following “Results” section refers mainly to the parent’s version
findings, unless otherwise specified.

Descriptive statistics (first Likert assumption)
For all JAMAR items, the median number of missing
responses was 2.3% (1.1–3.1%).
The response pattern for both PF and HRQoL was positively skewed toward normal functional ability and normal
HRQoL. All response choices were used for the different
HRQoL items, whereas a reduced number of response
choices were used for the PF item 15.
The mean and SD of the items within a scale were
roughly equivalent for the PF and for the HRQoL items
(data not shown). The median number of items marked as
not applicable was 1% (1–4%) for the PF and 8.5% (5–14%)
for the HRQoL.

Floor and ceiling effect
The median floor effect was 83.2% (73.2–89.4%) for the PF
items, 49.7% (42.8–53.1%) for the HRQoL PhH items, and
49.9% (39.7–62.2%) for the HRQoL-PsH items. The median
ceiling effect was 1.3% (0.6–1.7%) for the PF items, 3.0%
(3.0-4.3%) for the HRQoL PhH items, and 2.6% (2.2–4.8%)
for the HRQoL-PsH items. The median floor effect was
39.5% for the pain VAS, 35.6% for the disease activity VAS,
and 33% for the well-being VAS. The median ceiling effect
was 2.2% for the pain VAS, 1.9% for the disease activity
VAS and 1.5% for the well-being VAS.

Equal item‑scale correlations (second Likert
assumption)
Pearson item-scale correlations corrected for overlap were
roughly equivalent for items within a scale for 93% of the
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Table 1  Descriptive statistics (medians, first–third quartiles or absolute frequencies and %) for the 466 JIA patients
Systemic

Oligoarthritis

RF − polyarthritis

RF + polyarthritis

Psoriatic
Arthritis

Enthesitis
related
arthritis

Undifferentiated arthritis

All JIA
patients

Healthy

N = 64

N = 189

N = 105

N = 11

N = 15

N = 70

N = 12

N = 466

N = 93

133 (70.4%)

Female

35 (54.7%)

73 (69.5%)

9 (81.8%)

7 (46.7%)

11 (15.7%)

11 (91.7%)

279 (59.9%)#

49 (52.7%)

Age at visit

10 (7.2–13.3) 7.3 (5–11)

11.3
(7.6–14.5)

14.9 (14.4–
15.8)

13.3
(10.3–15)

14.5 (12.2–
16.5)

15.9 (15.4–
16.4)

10.8
(6.6–14.3)#

11.9 (9.6–
13.4)*

Age at onset

5.8 (2.4–8.9)

3.8 (1.7–7.3)

6.8 (3.8–10.8) 9.5 (7.8–13.2) 5.8 (3.2–11.4) 11.8
(9.3–13.6)

13.9 (12.8–
14.4)

6.3 (2.7–
10.8)#

Disease duration

2.9 (1.1–6.2)

2.3 (1-4.2)

2.9 (1.5–5.4)

4.1 (1.1–6.7)

4.8 (2.8–8.6)

2.4 (1.2–4.1)

1.9 (1.1-3)

2.6 (1.2–
4.6)*

ESR

12 (9–30)

14 (8–24)

15 (10–26)

24 (19–46)

12 (9–16)

12 (6–22)

13 (10–33)

14 (8–25)

MD VAS
(0–10 cm)

1 (0-2.5)

1.5 (0.5-4)

3.5 (1–5)

2.5 (2–6)

1 (0–3)

2 (1–4)

3.8 (3-5.3)

2 (0.5-4)#

No. swollen joints 0 (0–0)

0 (0–1)

0 (0–3)

1 (0–6)

0 (0–1)

0 (0–0)

0 (0–0)

0 (0–1)#

No. joints with
pain

0 (0–0)

0 (0–1)

1 (0–4)

2 (0–13)

0 (0–0)

0 (0–3)

2 (0.5-4)

0 (0–2)#

No. joints with
LOM

0 (0–1)

0 (0–1)

1 (0–2)

1 (0–2)

0 (0–0)

0 (0–1)

0 (0-0.5)

0 (0–1)#

No. active joints

0 (0–1)

1 (0–1)

1 (0–4)

2 (0–6)

0 (0–1)

0 (0–1)

0 (0-0.5)

0 (0–2)#

Active systemic
features

9 (14.1%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

9 (2%)#

ANA status

0 (0%)

33 (17.5%)

10 (9.5%)

2 (18.2%)

1 (6.7%)

0 (0%)

0 (0%)

46 (9.9%)#

Uveitis

0 (0%)

25 (13.4%)

8 (7.9%)

0 (0%)

0 (0%)

4 (5.9%)

0 (0%)

37 (8.1%)*

PF Total Score

1 (0-4.5)

1 (0–3)

3 (0–9)

3 (2–10)

0 (0–4)

1 (0–4)

2.5 (1.5–14)

2 (0–5)**

Pain VAS

0 (0-3.3)

1 (0–3)

2 (0-4.5)

2 (0–5)

0 (0-3.5)

1 (0-4.8)

4.5 (2.5–8.5)

1 (0–4)*

Disease activity
VAS

0 (0-2.5)

1 (0–3)

1.5 (0–4)

3.8 (0.5-5)

0.5 (0-2.5)

1 (0-3.5)

3.3 (2.8-6)

1 (0-3.5)*

Well-being VAS

1 (0-2.5)

1 (0–4)

2 (0–5)

5 (1.5–6.5)

1 (0–5)

1 (0-4.5)

4.3 (2.5–6.5)

1 (0-4.5)*

HRQoL-PhH

1 (0–4)

3 (0–5)

2 (1–5)

5 (1–5)

1 (0–4)

2 (0–4)

4 (1.5–8.5)

2 (0–5)*

0 (0–3)#

HRQoL-PsH

3 (1–5)

2 (0–4)

3 (1–5)

3 (1–8)

3 (0–6)

2 (0–5)

4 (2-6.5)

2 (1–5)

1.5 (0–3)**

HRQoL total
score

4 (2–9)

5 (2–9)

6 (2–10)

7 (6–13)

6 (1–8)

4.5 (1–9)

9 (5.5–12)

5 (2–10)

2 (0–6)#

Pain/swell. in > 1
joint

25 (39.1%)

118/188
(62.8%)

74/103
(71.8%)

8 (72.7%)

7 (46.7%)

38 (54.3%)

12 (100%)

282/463
(60.9%)#

5/92 (5.4%)#

Morning stiffness > 15 min

10 (15.6%)

29/185
(15.7%)

27/96 (28.1%) 3/10 (30%)

3/14 (21.4%)

15/69 (21.7%) 4 (33.3%)

91/450
(20.2%)

Subjective remission

23/63
(36.5%)

109/177
(61.6%)

72/93 (77.4%) 7/10 (70%)

9/14 (64.3%)

38/65 (58.5%) 10 (83.3%)

268/434
(61.8%)#

In treatment

48/63
(76.2%)

168/185
(90.8%)

89/101
(88.1%)

13/14
(92.9%)

61/67 (91%)

11 (91.7%)

401/453
(88.5%)

Reporting side
effects

22/48
(45.8%)

56/162
(34.6%)

38/86 (44.2%) 3 (27.3%)

5/12 (41.7%)

24/61 (39.3%) 6/10 (60%)

154/390
(39.5%)

Taking medication regularly

41/47
(87.2%)

151/163
(92.6%)

80/87 (92%)

10/13
(76.9%)

55/61 (90.2%) 8/11 (72.7%)

356/393
(90.6%)

With problems
7/32 (21.9%)
attending school

19/95 (20%)

15/56 (26.8%) 1/3 (33.3%)

2/6 (33.3%)

14/47 (29.8%) 4/8 (50%)

62/247
(25.1%)

Satisfied with dis- 34/61
ease outcome
(55.7%)

73/180
(40.6%)

38/97 (39.2%) 4/10 (40%)

11 (73.3%)

31/64 (48.4%) 3 (25%)

194/439
(44.2%)

11 (100%)

11 (100%)

0 (0–1)#

0 (0–0)#

2/90 (2.2%)#

3/81 (3.7%)#

Data related to the JAMAR refer to the 463 JIA patients and to the 92 healthy subjects for whom the questionnaire has been completed by the
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA Anti-nuclear antibodies, PF physical function (total
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. * p < 0.05, ** p < 0.001, # p < 0.0001
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Table 2  Main psychometric characteristics between the parent and child versions of the JAMAR

Missing values (1st–3rd quartiles)
Response pattern
Floor effect, median
PF
HRQoL PhH
HRQoL-PsH
Pain VAS
Disease activity VAS
Well-being VAS
Ceiling effect, median
PF
HRQoL PhH
HRQoL-PsH
Pain VAS
Disease activity VAS
Well-being VAS
Items with equivalent item-scale correlation
Items with item-scale correlation ≥ 0.4
Cronbach’s alpha
PF–LL
PF–HW
PF–US
HRQoL–PhH
HRQoL–PsH
Items with item-scale correlation lower than the Cronbach alpha
Test–retest intra-class correlation
PF total score
HRQoL–PhH
HRQoL–PsH
Spearman correlation with JIA core-set variables, median
PF
HRQoL PhH
HRQoL-PsH
Pain VAS
Disease activity VAS
Well-being VAS

Parent N = 463/555

Child N = 348/438

2.3% (1.1–3.1%)
PF and HRQoL positively skewed

1.9% (0.4–2.6%)
PF and HRQoL positively skewed

83.2%
49.7%
49.9%
39.5%
35.6%
33.0%

85.1%
54.0%
60.1%
34.2%
36.2%
34.5%

1.3%
3.0%
2.6%
2.2%
1.9%
1.5%
93% for PF, 100% for HRQoL
100% for PF, 100% for HRQoL

0.9%
4.0%
2.0%
1.1%
0.6%
0.6%
100% for PF, 100% for HRQoL
100% for PF,100% for HRQoL

0.87
0.90
0.84
0.87
0.82
100% for PF, 100% for HRQoL

0.85
0.88
0.79
0.88
0.78
100% for PF, 100% for HRQoL

0.96
0.78
0.86

0.83
0.94
0.77

0.5
0.5
0.3
0.4
0.4
0.4

0.5
0.5
0.3
0.4
0.4
0.4

JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical function, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist,
PF-US PF-upper segment

PF items, with the exception of item 15 and for 100% of the
HRQoL items.

Item internal consistency (third Likert assumption)

Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.87 for PF-LL, 0.90 for PF-HW, and
0.84 for PF-US. Cronbach’s alpha was 0.87 for HRQoL-PhH
and 0.82 for HRQoL-PsH.

Pearson item-scale correlations were ≥ 0.4 for 100% of items
of the PF and 100% of items of the HRQoL.
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Interscale correlation
The Pearson correlation of each item of the PF and the
HRQoL with all items included in the remaining scales of
the questionnaires was lower than the Cronbach’s alpha.

Test–retest reliability
Reliability was assessed in 18 JIA patients, by re-administering both versions (parent and child) of the JAMAR after
a median of 7 days (range 7–8 days). The intra-class correlation coefficients (ICC) for the PF total score showed
an almost perfect reproducibility (ICC = 0.96). The ICC
for the HRQoL PhH showed a substantial reproducibility
(ICC = 0.78) and the ICC for the HRQoL-PsH showed an
almost perfect reproducibility (ICC = 0.86).

Convergent validity
The Spearman correlation of the PF total score with the
JIA core set of outcome variables ranged from 0.4 to 0.5
(median = 0.5). The PF total score best correlation was
observed with the parent assessment of pain (r = 0.53,
p < 0.001). For the HRQoL, the median correlation of the
PhH with the JIA core set of outcome variables ranged from
0.3 to 0.6 (median = 0.5), whereas for the PsH ranged from
0.2 to 0.4 (median = 0.3). The HRQoL PhH showed the best
correlation with the parent’s assessment of pain (r = 0.64,
p < 0.001), while the HRQoL-PsH showed the best correlation with the parent global assessment of well-being
(r = 0.43, p < 0.001). The median correlations between the
pain VAS, the well-being VAS, and the disease activity VAS
and the physician-centred and laboratory measures were 0.4
(0.4–0.5), 0.4 (0.4–0.5), 0.4 (0.4–0.5), respectively.

Discussion
In this study, the Turkish version of the JAMAR was crossculturally adapted from the original standard English version
with three forward and two backward translations. According to the results of the validation analysis, the Turkish parent and patient versions of the JAMAR possess satisfactory
psychometric properties. The disease-specific components
of the questionnaire discriminated well between patients
with JIA and healthy controls. The PF total score and the
HRQoL PhH revealed to be able to discriminate between
the different JIA subtypes with the children diagnosed with
RF negative poly-arthritis, RF positive poly-arthritis and
undifferentiated arthritis having a higher degree of disability.
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Psychometric performances were good for all domains of
the JAMAR and the overall internal consistency was good
for all the domains.
In the external validity evaluation, the Spearman’s correlations of the PF and HRQoL scores with JIA core-set
parameters were moderate.
The results obtained for the parent version of the
JAMAR are very similar to those obtained for the child
version, which suggests that children are equally reliable
proxy reporters of their disease and health status as their
parents. The JAMAR is aimed to evaluate the side effects
of medications and school attendance, which are other
dimensions of daily life that were not previously considered by other HRQoL tools. This may provide useful information for intervention and follow-up in health care. In
conclusion, the Turkish version of the JAMAR was found
to have satisfactory psychometric properties and it is, thus,
a reliable and valid tool for the multidimensional assessment of children with JIA.
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